Announcement under Reg 30- Press Release

Registered & Corporate Office: AMANTA HEALTHCARE LIMITED 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat, INDIA. Tel.: 079 – 67777600 Email: info@amanta.co.in Website: www.amanta.co.in CIN: L24139GJ1994PLC023944 August 5, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G Phiroze Jeejeebhoy Towers, Bandra Kurla Complex Dalal Street, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Scrip Code: 544502 Trading Symbol: AMANTA Dear Sir/ Madam, Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Press Release With reference to the captioned subject, please find enclosed herewith Press Release on the Financial Results for the quarter ended June 30, 2026. You are requested to take the same on your records. Thanking you. Yours sincerely, For AMANTA HEALTHCARE LIMITED NIKHITA DINODIA Company Secretary & Compliance Officer Encl.: As above Factory: 876, N.H. No. 8, Hariyala, Kheda – 387411, Gujarat, India. Tel 2694287700 Fax 2694287720 Amanta Healthcare Limited announces Q1FY27 Results Stable Margins, Strategic Capacity Build-Out Continues. Ahmedabad, August 5th, 2026: Amanta Healthcare Limited (BSE: 544502, NSE: AMANTA) today announced the unaudited financial results for the quarter ended June 30, 2026. Rs. in Cr. Q1FY27 Q1FY26 Revenue 68.80 65.31 EBITDA 15.18 15.85 EBITDA Margin% 22% 24% PAT 3.31 3.50 PAT Margin% 4.8% 5.3% Q1FY27 Key Highlights: • Sustained revenue growth: Q1 FY27 revenue of ₹68.8 crore was achieved on the existing capacity base, registering a 5.4% YoY growth, driven by improved product mix and better price realizations. • Operational performance remains resilient: EBITDA for Q1FY27 stood at INR 15.2 Cr (includes other income) compared to INR 15.9 cr in Q1FY26. With margins moderating to 22% from 24%, a 200 bps decline, due to higher raw material, employee cost and other operating costs. • Profitability impacted by higher finance costs: PAT for Q1FY27 stood at INR 3.3 cr, declining 5.6% YoY from INR 3.5 cr, primarily due to higher finance costs on account of new Solar Term Loan, resulting in a PAT margin of 4.8%. • Capacity expansion to drive the next leg of growth: The Steriport plant is expected to be commissioned by Q2FY27, while the SVP expansion is targeted for Q4 FY27. Alongside the solar power plant, these initiatives are expected to materially enhance manufacturing capacity, cost efficiency and operating leverage over the coming years. Commenting on the performance for the quarter, Bhavesh Patel, Chairman & Managing Director, Amanta Healthcare Limited said, “Q1FY27 marked a period of steady performance for Amanta Healthcare, with revenue standing at ₹68.8 crore, reflecting a growth of 5.4% YoY, driven by an improved product mix and better price realizations. EBITDA stood at ₹15.2 crore, including other income, with EBITDA margins of 22% , despite higher raw material, employee cost and other operating costs. PAT stood at ₹3.3 crore, impacted largely by higher finance costs. The coming quarters present an exciting growth opportunity as we progress with our capacity expansion plans. The SteriPort facility is expected to be commissioned by Q2FY27, followed by the SVP expansion during Q4 FY27, creating a good headroom for future growth. The captive solar power project will further support cost efficiencies and strengthen our operating profile. With these initiatives progressing well, we are confident of building greater scale, enhancing profitability and unlocking sustainable growth opportunities across both domestic and export markets.” ABOUT AMANTA HEALTHCARE LIMITED Amanta, a pharmaceutical company engaged in development, manufacturing, and marketing of sterile liquid products, including both large and small volume parenteral (LVPs and SVPs). Using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies, the Company serves six therapeutic segments with products such as IV fluids, diluents, ophthalmic and respiratory care, and irrigation solutions. The packaging includes a wide range of closure systems and container volumes from 2 ml to 1000 ml. Amanta is led by experienced Management including our Promoter & CMD – Mr. Bhavesh Patel, a Mechanical Engineer and master’s degree in management with more than 30 years of experience. For more information, please visit: www.amanta.co.in Company contact Investor Relations Team Email: cs@amanta.co.in, Soumya Chhajed Tel: 079 6777 7600 Email- soumya@goindiaadvisors.com Mobile: +91-8619707750 Amanta Healthcare Ltd. 8th Floor, Shaligram Corporates, C. J. Marg, Ambli, Ahmedabad 380058 Gujarat, India.